Ensign Peak Advisors Inc grew its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating) by 53.1% during the third quarter, HoldingsChannel.com reports. The fund owned 77,753 shares of the company’s stock after buying an additional 26,959 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Kiniksa Pharmaceuticals were worth $998,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. Lazard Asset Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 52.2% during the 1st quarter. Lazard Asset Management LLC now owns 5,720 shares of the company’s stock valued at $56,000 after acquiring an additional 1,961 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Kiniksa Pharmaceuticals by 19.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,549 shares of the company’s stock worth $83,000 after purchasing an additional 1,385 shares during the period. Legal & General Group Plc lifted its stake in shares of Kiniksa Pharmaceuticals by 25.3% in the 2nd quarter. Legal & General Group Plc now owns 10,714 shares of the company’s stock worth $103,000 after purchasing an additional 2,162 shares during the period. Teacher Retirement System of Texas bought a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $130,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Kiniksa Pharmaceuticals by 23.8% in the 1st quarter. JPMorgan Chase & Co. now owns 17,825 shares of the company’s stock worth $177,000 after purchasing an additional 3,431 shares during the period. Hedge funds and other institutional investors own 42.98% of the company’s stock.
Wall Street Analysts Forecast Growth
KNSA has been the topic of several recent research reports. Wedbush lowered their price objective on shares of Kiniksa Pharmaceuticals from $26.00 to $20.00 in a research note on Wednesday, March 1st. JPMorgan Chase & Co. increased their price objective on shares of Kiniksa Pharmaceuticals from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday.
Kiniksa Pharmaceuticals Trading Down 2.1 %
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404.
- Get a free copy of the StockNews.com research report on Kiniksa Pharmaceuticals (KNSA)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Rating).
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.